Although numerous studies reported some changes of cortical silent period (CSP), an indicator of gamma-aminobutyric acid (GABA) function in central nervous system, in schizophrenia patients, it has been unknown how the disease stage and antipsychotic medication affect CSP values.
Methods:
The present study conducted a systematic review of previous literature comparing CSP between schizophrenia patients and healthy subjects, and then performed meta-analysis on the effects of (1) the disease stage and (2) antipsychotics on CSP.
Results:
(1) In the comparison of the disease stage comprising a total of 17 reports, there was no significant difference in CSP between patients under drug-naïve first-episode psychoses and healthy controls, or between patients with antipsychotic medication and healthy controls. (2) In the comparison of the antipsychotic class, patients treated with clozapine were longer in CSP compared to healthy controls. Patients treated with olanzapine/quetiapine or with other type of antipsychotics were not different from healthy controls. Regarding other type of antipsychotics, the iteration analysis after leaving out one literature showed that patients were shorter in CSP than healthy controls.
Conclusion:
The results showed that clozapine seems to surely prolong CSP, indicating the enhancement of GABA transmission via GABAB receptors, suggesting the possible relationship between the CSP prolongation by clozapine and its high efficacy in psychopathology. The finding of shorter CSP in patients with other type of antipsychotics was distinct from clozapine/olanzapine/quetiapine, but was difficult to interpret since this group included a variety of transcranial magnetic stimulation (TMS) methodologies and patients’ background.
Ahlgrén-RimpiläinenALauermaHKähkönenS, et al. (2013) Disrupted central inhibition after transcranial magnetic stimulation of motor cortex in schizophrenia with long-term antipsychotic treatment. ISRN Psychiatry2013: 876171.
2.
AkbarianSHuangHS (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Research Reviews52: 293–304.
3.
AndradeC (2016) Antipsychotic drugs in schizophrenia: Relative effects in patients with and without treatment resistance. The Journal of Clinical Psychiatry77: e1656–e1660.
4.
BajboujMGallinatJNiehausL, et al. (2004) Abnormalities of inhibitory neuronal mechanisms in the motor cortex of patients with schizophrenia. Pharmacopsychiatry37: 74–80.
5.
BeasleyCLZhangZJPattenI, et al. (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biological Psychiatry52: 708–715.
6.
BenesFM (1998) Model generation and testing to probe neural circuitry in the cingulate cortex of postmortem schizophrenic brain. Schizophrenia Bulletin24: 219–230.
7.
BunseTWobrockTStrubeW, et al. (2014) Motor cortical excitability assessed by transcranial magnetic stimulation in psychiatric disorders: A systematic review. Brain Stimulation7: 158–169.
8.
BuzsákiGGeislerCHenzeDA, et al. (2004) Interneuron diversity series: Circuit complexity and axon wiring economy of cortical interneurons. Trends in Neurosciences27: 186–193.
9.
CantelloRGianelliMCivardiC, et al. (1992) Magnetic brain stimulation: The silent period after the motor evoked potential. Neurology42: 1951–1959.
10.
CardinJACarlénMMeletisK, et al. (2009) Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature459: 663–667.
11.
CurleyAAArionDVolkDW, et al. (2011) Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: Clinical, protein, and cell type-specific features. The American Journal of Psychiatry168: 921–929.
12.
DaskalakisZJChristensenBKChenR, et al. (2002) Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Archives of General Psychiatry59: 347–354.
13.
DaskalakisZJChristensenBKFitzgeraldPB, et al. (2008) Increased cortical inhibition in persons with schizophrenia treated with clozapine. Journal of Psychopharmacology22: 203–209.
14.
DaveyNJPuriBKLewisHS, et al. (1997) Effects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenia. Journal of Neurology, Neurosurgery, and Psychiatry63: 468–473.
15.
de GoedeAATer BraackEMvan PuttenMJAM (2016) Single and paired pulse transcranial magnetic stimulation in drug naïve epilepsy. Clinical Neurophysiology127: 3140–3155.
16.
EgertonAModinosGFerreraD, et al. (2017) Neuroimaging studies of GABA in schizophrenia: A systematic review with meta-analysis. Translational Psychiatry7: e1147.
17.
EvensethLSMGabrielsenMSylteI (2020) The GABAB receptor-structure, ligand binding and drug development. Molecules25: 3093.
18.
FitzgeraldPBBrownTLDaskalakisZJ, et al. (2002a) A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. Psychiatry Research114: 11–22.
19.
FitzgeraldPBBrownTLDaskalakisZJ, et al. (2002b) A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology (Berl)162: 74–81.
20.
FitzgeraldPBBrownTLMarstonNA, et al. (2004) Reduced plastic brain responses in schizophrenia: A transcranial magnetic stimulation study. Schizophrenia Research71: 17–26.
21.
FrankELandgrebeMPoepplTB, et al. (2014) Antipsychotic treatment with quetiapine increases the cortical silent period. Schizophrenia Research156: 128–132.
22.
FriesPNeuenschwanderSEngelAK, et al. (2001) Rapid feature selective neuronal synchronization through correlated latency shifting. Nature Neuroscience4: 194–200.
23.
FritziusTBettlerB (2020) The organizing principle of GABAB receptor complexes: Physiological and pharmacological implications. Basic & Clinical Pharmacology & Toxicology126(Suppl. 6): 25–34.
24.
FuhrPAgostinoRHallettM (1991) Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalography and Clinical Neurophysiology81: 257–262.
25.
GoldsteinMEAndersonVMPillaiA, et al. (2015) Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. The International Journal of Neuropsychopharmacology18: pyu117.
26.
Gonzalez-BurgosGLewisDA (2008) GABA neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophrenia Bulletin34: 944–961.
27.
GuidottiAAutaJDavisJM, et al. (2000) Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Archives of General Psychiatry57: 1061–1069.
28.
HasanAWobrockTGrefkesC, et al. (2012a) Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: A cross-sectional study. Biological Psychiatry72: 744–751.
29.
HasanANitscheMAHerrmannM, et al. (2012b) Impaired long-term depression in schizophrenia: A cathodal tDCS pilot study. Brain Stimulation5: 475–483.
30.
HasanAMisewitschKNitscheMA, et al. (2013) Impaired motor cortex responses in non-psychotic first-degree relatives of schizophrenia patients: A cathodal tDCS pilot study. Brain Stimulation6: 821–829.
31.
HashimotoTVolkDWEgganSM, et al. (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. The Journal of Neuroscience23: 6315–6326.
32.
HerbsmanTForsterLMolnarC, et al. (2009) Motor threshold in transcranial magnetic stimulation: The impact of white matter fiber orientation and skull-to-cortex distance. Human Brain Mapping30: 2044–2055.
33.
HupfeldKESwansonCWFlingBW, et al. (2020) TMS-induced silent periods: A review of methods and call for consistency. Journal of Neuroscience Methods346: 108950.
34.
IshikawaMMizukamiKIwakiriM, et al. (2005) Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neuroscience Letters383: 272–277.
35.
IwataYNakajimaSPlitmanE, et al. (2019) Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: A cross-sectional 3T proton magnetic resonance spectroscopy study. Biological Psychiatry85: 596–605.
36.
KasterTSde JesusDRadhuN, et al. (2015) Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Schizophrenia Research165: 157–162.
37.
KonradiCYangCKZimmermanEI, et al. (2011) Hippocampal interneurons are abnormal in schizophrenia. Schizophrenia Research131: 165–173.
38.
KubotaMMoriguchiSTakahataK, et al. (2020) Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Schizophrenia Research222: 122–132.
39.
KurokiTNagaoNNakaharaT (2008) Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Progress in Brain Research172: 199–212.
40.
LewisDAHashimotoTVolkDW, et al. (2005) Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience6: 312–324.
41.
LewisDAChoRYCarterCS, et al. (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. The American Journal of Psychiatry165: 1585–1593.
42.
LewisDACurleyAAGlausierJR, et al. (2012) Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences35: 57–67.
43.
LiuSKFitzgeraldPBDaigleM, et al. (2009) The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biological Psychiatry65: 503–509.
44.
MiyazawaAKanaharaNNakataY, et al. (2021) Clozapine prolongs cortical silent period in patients with treatment-resistant schizophrenia. Psychopharmacology Bulletin51: 20–30.
45.
MiyazawaAKanaharaNKogureM, et al. (2022) A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia. Molecular Biology Reports. Epub ahead of print 29 November. DOI: 10.1007/s11033-021-07019-z.
46.
MizukamiKSasakiMIshikawaM, et al. (2000) Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia. Neuroscience Letters283: 101–104.
47.
MoherDLiberatiATetzlaffJ, et al. (2010) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery8: 336–341.
48.
NairPCMcKinnonRAMinersJO, et al. (2020) Binding of clozapine to the GABA(B) receptor: Clinical and structural insights. Molecular Psychiatry25: 1910–1919.
49.
O’ConnorWTO’SheaSD (2015) Clozapine and GABA transmission in schizophrenia disease models: Establishing principles to guide treatments. Pharmacology & Therapeutics150: 47–80.
50.
PrikrylRUstohalLKucerovaHP, et al. (2009) Paliperidon mediated modification of cortical inhibition. Neuroendocrinology Letters30: 396–399.
51.
PuriBKDaveyNJEllawayPH, et al. (1996) An investigation of motor function in schizophrenia using transcranial magnetic stimulation of the motor cortex. British Journal of Psychiatry169: 690–695.
52.
RadhuNde JesusDRRavindranLN, et al. (2013) A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clinical Neurophysiology124: 1309–1320.
53.
RoehAMalchowBLevoldK, et al. (2018) Effects of three months of aerobic endurance training on motor cortical excitability in schizophrenia patients and healthy subjects. Neuropsychobiology12: 1–8.
54.
RuzickaWBZhubiAVeldicM, et al. (2007) Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Molecular Psychiatry12: 385–397.
55.
SchmidtMJMirnicsK (2015) Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology40: 190–206.
56.
SchwartzTLSachdevaSStahlSM, et al. (2012) Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Frontiers in Pharmacology3: 95.
57.
SiebnerHRDressnandtJAuerC, et al. (1998) Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle & Nerve21: 1209–1212.
58.
SohalVSZhangFYizharO, et al. (2009) Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature459: 698–702.
59.
SoubasiEChroniEGourzisP, et al. (2010) Cortical motor neurophysiology of patients with schizophrenia: A study using transcranial magnetic stimulation. Psychiatry Research176: 132–136.
60.
SouzaJSKayoMTassellI, et al. (2013) Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: Evidence from a systematic review and meta-analyses. CNS Spectrums18: 82–89.
61.
StangA (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology25: 603–605.
62.
StroupDFBerlinJAMortonSC, et al. (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA283: 2008–2012.
63.
StrubeWWobrockTBunseT, et al. (2014) Impairments in motor-cortical inhibitory networks across recent-onset and chronic schizophrenia: A cross-sectional TMS Study. Behavioural Brain Research264: 17–25.
64.
Tallon-BaudryCBertrandOPeronnetF, et al. (1998) Induced gamma-band activity during the delay of a visual short-term memory task in humans. The Journal of Neuroscience18: 4244–4254.
65.
TangYZhangTEdelmanB, et al. (2014) Prolonged cortical silent period among drug-naive subjects at ultra-high risk of psychosis. Schizophrenia Research160: 124–130.
66.
UstohalLMayerovaMHublovaV, et al. (2017) Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. Journal of Psychopharmacology31: 500–504.
67.
WerhahnKJKuneschENoachtarS, et al. (1999) Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. The Journal of Physiology 517(Pt 2): 591–597.
68.
WobrockTSchneiderMKadovicD, et al. (2008) Reduced cortical inhibition in first-episode schizophrenia. Schizophrenia Research105: 252–261.
69.
WobrockTSchneider-AxmannTRetzW, et al. (2009) Motor circuit abnormalities in first-episode schizophrenia assessed with transcranial magnetic stimulation. Pharmacopsychiatry42: 194–201.
70.
WooTUMillerJLLewisDA (1997) Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. The American Journal of Psychiatry154: 1013–1015.
71.
WuYBlichowskiMDaskalakisZJ, et al. (2011) Evidence that clozapine directly interacts on the GABAB receptor. NeuroReport22: 637–641.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
